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Abstract: Anemia is the most prevalent extraintestinal complication
of inflammatory bowel disease (IBD). Our aim was to evaluate the
comparative efficacy and harm of intravenous (IV) versus oral iron
supplementation for correcting anemia in adult IBD patients.rgirios Tsantes, M
, and Silvio Danese, MD, PhD
iron-deficiency anemia. Medline, Embase, Scopus, and the Web of
Science database were searched through July 2015. The Cochrane
Central Register of Controlled Trials, the WHO International Clinical
Trials Registry Platform, the ClinicalTrials.gov, and international con-
ference proceedings were also investigated. Two reviewers indepen-
dently abstracted study data and outcomes, and rated each trial’s risk-of-
bias. Pooled odds ratio (OR) estimates with their 95% CIs were
calculated using fixed- and random-effects models.
Five eligible studies, including 694 IBD patients, were identified. In
meta-analysis, IV iron demonstrated a higher efficacy in achieving a
hemoglobin rise of 2.0 g/dL as compared to oral iron (OR: 1.57, 95%
CI: 1.13, 2.18). Treatment discontinuation rates, due to adverse events
or intolerance, were lower in the IV iron groups (OR: 0.27, 95% CI:
0.13, 0.59). Similarly, the occurrence of gastrointestinal adverse events
was consistently lower in the IV iron groups. On the contrary, serious
adverse events (SAEs) were more frequently reported among patients
receiving IV iron preparations (OR: 4.57, 95%CI: 1.11, 18.8); however,
the majority of the reported SAEs were judged as unrelated or unlikely
to be related to the study medication. We found no evidence of
publication bias, or between-study heterogeneity, across all analyses.
Risk of bias was high across primary studies, because patients and
personnel were not blinded to the intervention.
IV iron appears to be more effective and better tolerated than oral
iron for the treatment of IBD-associated anemia.
(Medicine 95(2):e2308)
Abbreviations: CD = Crohn’s disease, CI = confidence interval,
GRADE = Grading of Recommendations Assessment,
Development and Evaluation, IBD = inflammatory bowel disease,
IV = intravenous, OR = odds ratio, PRISMA = preferred reporting
items for systematic reviews and meta-analyses, PROSPERO =
international prospective register of systematic reviews, RCT =
randomized controlled trial, RoB = risk of bias, SAE = serious
adverse event, UC = ulcerative colitis.
INTRODUCTION
A nemia is considered the most frequent extraintestinal mani-festation of inflammatory bowel disease (IBD), usually
complicating the course both in ulcerative colitis (UC) andCrohn
disease (CD).1,2 It is detected in up to 20%of outpatients and70%
of hospitalized patients with IBD.3–5 In the majority of cases,
IBD-associated anemia represents a combination of chronic iron
deficiency and anemia of chronic disease.6,7 Other less frequent
causes include vitaminB12 and folate deficiency, and toxic effects
of medications.8,9 At the patient level, anemia significantlynd the physical, emotional, and cognitive
economic level, it increases the risk of
gery, as well as healthcare costs.11
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Iron supplementation is recommended in all IBD patients
when iron-deficiency anemia is present.8 This can be under-
taken using oral or intravenous (IV) iron preparations. Oral iron
is convenient and inexpensive, but its efficacy is limited by
poor absorption, intolerance, and frequent adverse effects. IV
iron is better tolerated; however, the costs associated with IV
iron administration might limit its widespread use.12 The
recent European Crohn’s and Colitis Organization (ECCO)
guidelines8 conclude that ‘‘IV iron is more effective, shows a
faster response, and is better tolerated than oral iron’’ and state
that ‘‘IV iron should be considered as first line treatment in
patients with clinically active IBD,with previous intolerance to
oral iron, with hemoglobin below 10.0 g/dL, and in patients
who need erythropoiesis-stimulating agents; while oral iron
may be used in patients with mild anemia, whose disease is
clinically inactive, andwho have not been previously intolerant
to oral iron.’’8
Nevertheless, there is still much controversy about whether
iron should be supplemented orally or intravenously, with a
great number of physicians still being uncertain as to which
treatment modality they should select for their patients.13 This
uncertainty has been amplified by a very recent meta-analysis
that found no statistically significant difference between IV and
oral iron in correcting iron-deficiency anemia in IBD.14 How-
ever, we have spotted important data extraction errors in that
study (see Appendix, http://links.lww.com/MD/A611) raising
serious doubts about the validity of reported conclusions. As a
result, we decided it was important to start afresh; thus our
objective was to conduct a new systematic review and meta-
analysis of published trials assessing and comparing the effi-
cacy and harm of IV versus oral iron supplementation for
correcting iron-deficiency anemia in patients with IBD, and
to provide a useful evidence summary to support clinical
decision making.
METHODS
Protocol and Registration
Our study protocol15 is registered with the International
Prospective Register of Systematic Reviews (PROSPERO,
http://www.crd.york.ac.uk/prospero). The current systematic
review and meta-analysis was performed adhering to the guide-
lines established by the PRISMA (Preferred Reporting Items for
Systematic Reviews and Meta-analyses) statement.16
The study did not involve any experiment on humans or
animals, thus an ethical approval was not necessary.
Data Sources and Search Strategy
A systematic search of Medline, Embase, Scopus, and the
Web of Science database was conducted from the date of
inception of each database to July 20, 2015. Search terms
included: crohn’s disease, ulcerative colitis, or inflammatory
bowel disease, combined with iron, ferric, ferrous, or anemia.
The search was limited to clinical trials and humans. No
language restrictions were imposed.
We also searched the Cochrane Central Register of Con-
trolled Trials, the Cochrane Inflammatory Bowel Disease Group
Specialized Trials Register, the WHO International Clinical
Trials Registry Platform, and the ClinicalTrials.gov website
for completed but unpublished studies; and recent international
conference proceedings (European Crohn’s and Colitis Organ-
Bonovas et alisation, 2011–2015; Digestive Disease Week, 2010–2015; and
the United European Gastroenterology Week, 2010–2014).
Two investigators independently examined the search results
2 | www.md-journal.comand screened the titles and abstracts to exclude any reports that
were clearly irrelevant. The full text of the remaining articles
was critically assessed for eligibility, and their reference lists (as
well as of relevant reviews and meta-analyses) were inspected to
identify further eligible studies. We also asked field experts to
provide additional evidences.
Study Selection and Data Extraction
In this meta-analysis, we considered randomized con-
trolled trials (RCTs) with either a parallel or crossover design,
having enrolled adult patients with IBD, and comparing IV
versus oral iron supplementation against each other (ie, head-to-
head trials) for correcting anemia. We accepted any definition of
anemia used by study authors, provided that all male partici-
pants had <13.0 g/dL and all the female participants had
<12.0 g/dL of hemoglobin (ie, all participants met the WHO
criteria for anemia for adult males and nonpregnant females17).
However, we are aware that some potential participants who met
the WHO criteria may have not been enrolled in a trial because it
used a different level of hemoglobin to diagnose anemia (eg,
11.0 g/dL of hemoglobin).
Studies were excluded if they were observational; did not
investigate patients with IBD; did not report (or provided
insufficient data for) the outcomes of interest; or were con-
ducted in pediatric populations.
Our primary (efficacy) outcome was the effect of treat-
ments on the hemoglobin response, defined as the rate of
patients who achieved an increase of at least 2.0 g/dL in
hemoglobin concentration at the end of the follow-up.
As secondary (safety) outcomes we studied: the rates of
discontinuation of the intervention due to adverse events or
intolerance; the occurrence of serious adverse events (SAEs),
which are defined as any untoward medical occurrence that
results in death, requires hospital admission or prolongation of
existing hospital stay, causes persistent or significant disability/
incapacity, or is life threatening18; and the rates of gastrointes-
tinal adverse events (nausea, vomiting, abdominal pain, and
diarrhea).
Data extraction was undertaken by 2 independent
reviewers. Any discrepancy was resolved by consensus, refer-
ring back to the original article. The following data were
extracted from each study: first author’s name, journal and year
of publication, study design and duration, number of partici-
pants, disease (eg, UC, CD), patient characteristics (age, con-
comitant treatments, duration of disease), details of iron
supplementation, including dose, route, frequency, and
duration, and rates of participants with events (ie, primary
and secondary outcomes) reported for the IV and the oral
iron groups.
Assessment of Risk of Bias
We evaluated the risk of bias (RoB) in included studies
using the Cochrane Collaboration’s tool,19,20 which addresses
the following key domains: sequence generation; allocation
concealment; blinding of participants, personnel, and outcome
assessors; incomplete outcome data; selective outcome report-
ing; and other sources of bias (eg, extreme baseline imbalances
in prognostic factors, differential distributions of IBD type,
etc.). These items were considered for the RoB assessment and
were classified as ‘‘adequate’’ (low RoB), ‘‘inadequate’’ (high
Medicine  Volume 95, Number 2, January 2016RoB), or ‘‘unclear’’ (uncertain RoB). Studies with adequate
procedures in all domains were considered to have a low RoB;
ones with inadequate procedures in 1 or more domains were
Copyright # 2016 Wolters Kluwer Health, Inc. All rights reserved.
considered to have a high RoB; and those with unclear pro-
cedures in 1 or more domains were considered to have unclear
RoB. Discrepancies among reviewers were discussed, and
agreement was reached by consensus.
Data Synthesis and Analysis
The odds ratio (OR) was the metric of choice in all
comparisons. Study-level ORs and their 95% CIs were calcu-
lated in accordance with the intention-to-treat principle:
analysis was based on the total number of randomly assigned
participants, irrespective of how the original study investigators
analyzed the data. All drop-outs were treated as treatment
failures (ie, failure to achieve an increase of at least 2.0 g/dL
in hemoglobin concentration).
When no events occurred in 1 group of the trial, we used a
continuity correction that was inversely proportional to the
relative size of the opposite group. In particular, the continuity
correction for the IV iron group was 1/(Rþ1), where R is the
ratio of oral iron group to IV iron group sizes. Similarly, the
continuity correction for the oral iron group was R/(Rþ1). This
methodological approach outperforms the use of a constant
continuity correction of 0.5 in a setting of sparse data and
imbalanced study groups.21 Trials reporting zero-event data for
both study groups were excluded from the analyses.
We used 2 techniques to calculate the pooled relative
effect estimates: the fixed-effects model (Mantel–Haenszel
approach),22 and the random-effects model (DerSimonian
and Laird approach).23 In the absence of heterogeneity, the
fixed- and the random-effects model provide very similar
results. When heterogeneity is found, the random-effects model
might be more prudent, though both techniques may be biased.
To examine the stability of the results, we also performed a
‘‘leave-one-out’’ sensitivity analysis.24 The scope of this
Medicine  Volume 95, Number 2, January 2016approach was to evaluate the influence of individual studies,
by calculating the summary effect estimate in the absence of
each study.
FIGURE 1. Summary of the evidence search and selection pr
controlled trials.
Copyright # 2016 Wolters Kluwer Health, Inc. All rights reserved.Selective outcome reporting or publication bias was
assessed using the Begg’s adjusted rank correlation test,25
and the Egger’s regression asymmetry test.26 The between-
study heterogeneity was evaluated using the Cochran’s Q test,27
with a 0.10 level of significance, and the I2 statistic,28,29 which
describes the percentage variation across studies that is due to
heterogeneity rather than chance. Negative values of I2 were put
equal to zero, so that it lies between 0% and 100%. An I2 value
<40% was considered as indicative of ‘‘not important hetero-
geneity’’ and a value over 75% as indicative of ‘‘considerable
heterogeneity.’’30
The quality of the meta-analytic evidence, for each of the
outcomes, was assessed using GRADE (Grading of Recom-
mendations Assessment, Development and Evaluation).31,32
For all analyses, we used the R software environment,33
version 3.1.1, and the ‘‘meta’’ package for R,34 version 4.2-0.
All P values are 2-tailed. For all statistical tests (except for
heterogeneity), a P value <0.05 was regarded as statistically
significant.
RESULTS
Search Results
A summary of the literature search and selection process is
presented in Figure 1 (Flow Diagram). Five RCTs35–39 com-
paring IV versus oral iron (head-to-head) for correcting iron-
deficiency anemia in IBD patients met the eligibility criteria and
were further analyzed.
Iron sucrose was the most frequent IV iron preparation
used in the included trials,35,37,39 followed by iron isomalto-
side,38 and ferric carboxymaltose.36 On the other hand, oral iron
sulfate was used in 4 studies,36–39 and oral ferrous fumarate in
1.35 The number of randomized participants varied between 19
Intravenous Versus Oral Iron for IBD-Associated Anemiaand 338 in the included studies, and the follow-up times from 2
to 20 weeks. Imbalance was observed between the group sizes
within studies (ratio, 1:1 or 2:1). The publication dates ranged
ocess. IBD¼ inflammatory bowel disease, RCTs¼ randomized
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FIGURE 2. Risk-of-bias assessment for the randomized trials
Medicine  Volume 95, Number 2, January 2016between 2005 and 2013. A summary of the trials’ characteristics
is given in Table 1.
Risk of Bias in Included Studies
Assessment of the RCTs, by use of the Cochrane Collab-
oration’s tool, revealed high RoB across the 5 studies.35–39
Participants and personnel were not blinded to the interventions.
We are aware that it is impossible to blind trials comparing oral
iron with IV, as oral iron is indicated by black stools; however,
open-label design represents a major weakness, as it can bias the
results by affecting either the actual patient outcomes (eg,
differential drop-outs) or the outcomes’ assessment (consider-
ing how subjective the evaluation of gastrointestinal adverse
events or iron intolerance may be). For this reason, we con-
included in the meta-analysis. Symbols: green (þ), low risk of
bias; yellow (?), unclear risk of bias; red (), high risk of bias.sidered the whole group of trials to have a high RoB with regard
to the ‘‘blinding of participants and personnel’’ domain. Quality
assessment items are summarized in Figure 2.
FIGURE 3. Forest plot for hemoglobin response (ie, increase of 2.0g
confidence interval, IV¼ intravenous, OR¼odds ratio.
Copyright # 2016 Wolters Kluwer Health, Inc. All rights reserved.Results of Meta-Analyses
Hemoglobin Increase 2.0 g/dL
(Primary Outcome)
Five RCTs contributed to this analysis.35–39 Each trial
reported a higher percentage of responders (defined as the
proportion of patients with a hemoglobin increase of 2.0 g/
dL) in the IV iron group as compared to the oral iron group. The
overall response rate, on all 5 RCTs, was 65.6% in the IV iron
groups, and 52.1% in the oral iron groups.
In meta-analysis, IV iron demonstrated a higher efficacy
in achieving a hemoglobin rise of 2.0 g/dL in comparison to
oral iron. The pooled effect estimate was statistically signifi-
cant under both a fixed-effects (OR: 1.59, 95% CI: 1.15, 2.20)
and a random-effects model (OR: 1.57, 95% CI: 1.13, 2.18).
The ORs with their 95% CIs for the individual studies, and
the pooled results, are presented in a forest plot (Figure 3).
The Cochran’s Q test had a P value of 0.69 and the corre-
sponding I2 statistic was 0%, both indicating very little
variability between the studies, although these statistical tests
may be subject to type II error (lack of power to detect
heterogeneity) given the small number of studies. The P
values for the tests of Begg’s and Egger’s were P¼ 0.22
and P¼ 0.12, respectively, suggesting a low probability of
publication bias (Table 2). The ‘‘leave-one-out’’ sensitivity
analysis, removing 1 study at a time, confirmed the robust-
ness of our results (Figure 4).
Treatment Discontinuation due to Adverse
Events or Intolerance
Treatment discontinuation rate was lower in the IV iron
groups (2.5%) as compared to the oral iron groups (10.9%).
The summary effect estimate was statistically significant,
either assuming a fixed-effects (OR: 0.24, 95% CI: 0.12,
0.49) or a random-effects model (OR: 0.27, 95% CI: 0.13,
0.59; Table 2). Results from the primary studies, and meta-
analysis, are shown in Figure 5. Again, we found no evidence
of publication bias (Begg’s, P¼ 0.99; Egger’s, P¼ 0.13) or
heterogeneity (Cochran’s Q test, P¼ 0.42; I2¼ 0%) among
the primary studies.
It is important to note, here, that the selection criteria
applied in 3 studies,36,38,39 excluding patients with known
intolerance to oral iron, may have caused a selection bias
toward a favorable tolerability for oral iron in these studies,
and thus, a bias toward the null (no difference) for the ‘‘treat-
ment discontinuation’’ outcome in our meta-analysis. Hence, in
Intravenous Versus Oral Iron for IBD-Associated Anemiaunselected IBD populations, the tolerability to oral iron may
be lower, and treatment discontinuation rates even higher
(than 10.9%).
/dL): results from individual studies and meta-analysis. CI¼ confi-
www.md-journal.com | 5
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TABLE 2. Meta-Analysis Results
Fixed-Effects
Model
Random-Effects
Model
Tests of
Homogeneity
Tests of
Publication Bias
Outcome
No. of
RCTs OR (95% CI) OR (95% CI)
Q Value
(df) P Value I2, %
Begg’s
P Value
Egger’s
P Value
Hemoglobin increase 2 g/dL 5 1.59 (1.15, 2.20) 1.57 (1.13, 2.18) 2.27 (4) 0.69 0 0.22 0.12
Discontinuation of the treatment
due to adverse events or
intolerance
5 0.24 (0.12, 0.49) 0.27 (0.13, 0.59) 3.87 (4) 0.42 0 0.99 0.13
Serious adverse events 4 5.45 (1.35, 22.0) 4.57 (1.11, 18.8) 0.61 (3) 0.90 0 0.99 0.64
Gastrointestinal adverse events
Nausea 4 0.40 (0.15, 1.05) 0.43 (0.16, 1.17) 1.08 (3) 0.78 0 0.73 0.73
Vomiting 3 0.27 (0.07, 1.00) 0.28 (0.07, 1.07) 0.36 (2) 0.83 0 0.30 0.26
Abdominal pain 5 0.22 (0.09, 0.53) 0.28 (0.07, 1.16) 6.33 (4) 0.18 37 0.46 0.11
Diarrhea 5 0.15 (0.06, 0.39) 0.18 (0.07, 0.50) 2.20 (4) 0.70 0 0.99 0.13
CI¼ confidence interval, df¼ degrees of freedom, OR¼ odds ratio, RCT
FIGURE 4. ‘‘Leave-one-out’’ sensitivity analysis for hemoglobin
response (ie, increase of 2.0g/dL): pooled estimates are from
Bonovas et al Medicine  Volume 95, Number 2, January 2016Serious Adverse Events
The occurrence of SAEs was 4.2% in the IV iron groups
(19 events), while only 1 was reported in the oral iron groups
(0.4%). Continuity corrections, inversely proportional to the
relative size of the opposite arm, were used in the analysis.
Exposure to IV iron was associated with a significant increase in
the risk of SAEs (fixed-effects model, OR: 5.45, 95% CI: 1.35,
random-effects models, with 1 study omitted at a time. CI¼
confidence interval, OR¼odds ratio.22.0; and random-effects model, OR: 4.57, 95% CI: 1.11, 18.8).
The ORs with their 95% CIs from the primary trials, and the
pooled results, are presented in Figure 6. We found no evidence
FIGURE 5. Forest plot for treatment discontinuation, due to adverse
analysis. CI¼ confidence interval, IV¼ intravenous, OR¼odds ratio.
6 | www.md-journal.comof publication bias (Begg’s, P¼ 0.99; Egger’s, P¼ 0.64) or
heterogeneity (Cochran’s Q test, P¼ 0.90; I2¼ 0%) among the
studies (Table 2).
At this point, we should note that no cases of anaphylactic
shock reactions were reported, and that the vast majority of the
reported SAEs (18 of 20) were considered by the Safety Boards
as unrelated, or unlikely to be related, to the study medications.
Gastrointestinal Adverse Events
The occurrence of gastrointestinal adverse events was
consistently lower in the IV iron groups in comparison to the
oral iron groups (nausea: 1.6% vs 4.9%, vomiting: 1.0% vs
6.8%, abdominal pain: 1.3% vs 7.9%, and diarrhea: 0.9% vs
8.3%). The fixed-effects summary estimates were statistically
significant for abdominal pain (OR: 0.22, 95% CI: 0.09, 0.53)
and diarrhea (OR: 0.15, 95% CI: 0.06, 0.39), but not for nausea
(OR: 0.40, 95% CI: 0.15, 1.05) and vomiting (OR: 0.27, 95%
CI: 0.07, 1.00). In each analysis, we found no evidence of
publication bias or heterogeneity between studies (Table 2).
s¼ randomized controlled trials.Quali(i)
event
Copty of the Evidence
n this meta-analysis, the quality of synthesized evidence is
d as ‘‘moderate’’ for the following reasons:the data were derived from RCTs (randomized study
design is considered the gold standard for assessing
therapeutic interventions),40
s or intolerance: results from individual studies and meta-
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th of evidence is shown in Table 3.
E 3. Summary of Findings
Illustrative Comparative R
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Oral Iron
lobin increase 2 g/dL 520 per 1000 633
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ent discontinuation due to adverse
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corresponding (IV group) risk is based on the assumed (control gro
relative effect estimate and its 95% CI come from a fixed-effects m
overall quality of the synthesized evidence is judged as ‘‘moderate’’
design is considered the gold standard for assessing therapeutic interve
Es); the results are consistent (heterogeneity was very low across stud
oB, because participants and personnel were not blinded to the interven
ence means that ‘‘we are moderately confident in the effect estimate. T
ibility that it is substantially different.’’31
confidence interval, GRADE¼Grading of Recommendations Assess
odds ratio, RCT ¼ randomized controlled trial, RoB¼ risk of bias, S
ight # 2016 Wolters Kluwer Health, Inc. All rights reserved.DISCUSSION
Anemia is the most prevalent extraintestinal complication
of IBD and needs appropriate therapeutic approach. The aim of
treatment is to supply enough iron to normalize hemoglobin
concentrations and replenish iron stores, and thereby to improve
quality of life, symptoms, and disease prognosis.41 Although
iron supplementation is recommended in all IBD patients
diagnosed with iron-deficiency anemia, a large number of
physicians are uncertain as to which treatment modality they
should select.13
In this systematic review and meta-analysis, we incorpor-
ated 5 RCTs comparing IV versus oral iron supplementation
individual studies and meta-analysis. CI¼ confidence interval,(head-to-head trials) for correcting iron-deficiency anemia in
adult patients with IBD. IV iron demonstrated a higher efficacy
in achieving a hemoglobin response of at least 2.0 g/dL (primary
isks (95% CI)
esponding Risk
IV Iron
per 1000 Relative effect (95% CI): OR, 1.59 (1.15, 2.20)
–704) No. of participants: 694
No. of RCTs: 5
Quality of evidence (GRADE):  (moderate)
er 1000 Relative effect (95% CI): OR, 0.24 (0.12, 0.49)
57) No. of participants: 694
No. of RCTs: 5
Quality of evidence (GRADE):  (moderate)
er 1000 Relative effect (95% CI): OR, 5.45 (1.35, 22.0)
1) No. of participants: 675
No. of RCTs: 4
Quality of evidence (GRADE):  (very low)
ia.
event rate across the trial groups receiving oral iron.
up) risk and the relative effect estimate (odds ratio).
eta-analytic model.
for the following reasons: Data were derived from RCTs (randomized
ntions); the meta-analytic effect estimates are relatively precise (except
ies); but all the RCTs included in the meta-analysis are characterized by
tion (a fact that downgrades the quality of evidence). A moderate quality
he true effect is likely to be close to the estimate of the effect, but there is
ment, Development and Evaluation, IBD¼ inflammatory bowel disease,
AE ¼ serious adverse event.
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outcome) as compared to oral iron supplementation. Treatment
discontinuation rates due to adverse events or intolerance were
also lower among patients receiving IV iron preparations.
Similarly, the occurrence of gastrointestinal adverse events
(nausea, vomiting, abdominal pain, and diarrhea) was consist-
ently lower in the IV iron study groups in comparison to the oral
iron groups. Alarmingly, SAEs were more frequently reported
among patients receiving IV iron preparations. However, the
majority of the reported events were judged by the Safety
Boards as unrelated or unlikely to be related to the study
medication; thus a causal relationship cannot be inferred.
In the recent literature we have identified 3 relevant
systematic reviews14,42,43 discussing the diagnosis and treat-
ment of anemia in IBD. The review by Nielsen et al42 was wide
in scope and included several randomized and nonrandomized
prospective studies, with or without control groups, but did not
include a meta-analysis. The earlier review and meta-analysis
by Avni et al43 did not include the recent larger trial by Reinisch
et al,38 which contributed about half the patients in our analysis.
In addition, Avni et al43 performed an ‘‘as-treated’’ (per-pro-
tocol) analysis, while ours was by intention-to-treat; the latter is
recommended as the least biased way to estimate intervention
effects in randomized trials.44 They found a pooled effect
estimate similar to our own (Relative Risk: 1.25, 95% CI:
1.04, 1.51) but our analysis improves the precision and
reliability of this finding. Finally, we have the very recent
systematic review andmeta-analysis by Abhyankar andMoss,14
which had failed to find any significant difference between IV
and oral iron on hemoglobin response, and was the motivation
for undertaking our new review. That study included the same 5
trials (ie, we could not identify any additional trials) but was
compromised by important data extraction errors (see
Appendix, http://links.lww.com/MD/A611); ultimately its con-
clusions came out as invalid, since our rerun of the meta-
analysis clearly demonstrates a statistically significantly higher
efficacy of IV iron in achieving a hemoglobin response of at
least 2.0 g/dL compared to oral iron.
In our study, a rigorous and extensive literature searchwas
conducted; data extraction was carefully undertaken by 2
independent reviewers; studies were analyzed on an inten-
tion-to-treat basis; and appropriate meta-analytic methods
were applied in the evidence synthesis to account for sparse
data and imbalanced study groups. Moreover, though the
primary studies had different inclusion and exclusion criteria,
and follow-up duration, very little heterogeneity was identified
across all analyses, supporting the robustness of our findings.
However, our meta-analysis has some limitations. All the
included trials were characterized by high RoB, as assessed
with the Cochrane Collaboration’s tool; treatments were not
evaluated in terms of cost, which is a key consideration in
clinical practice; and no distinction was made between differ-
ent preparations of IV or oral iron. According to GRADE, the
quality of evidence (certainty of associations) in this review is
moderate. This evidence, along with the treatment costs,
patients’ values and preferences,45 and other factors (clinical
disease activity, severity of anemia, and previous intolerance to
oral iron) should be considered to inform clinical decision
making. Nevertheless, further high-quality (and adequately
powered) randomized research, with clearly defined patient
populations (eg, UC or CD, with mild, moderate, or severe
anemia, etc.), would be very welcome, andmay be necessary to
Bonovas et alextend our current knowledge on the alternative treatment
modalities for correcting iron-deficiency anemia in patients
with IBD.
8 | www.md-journal.comIn conclusion, synthesis of the existing randomized evi-
dence supports that IV iron is more effective and better tolerated
than oral iron supplementation for correcting anemia in adult
patients with IBD.
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